tert-butyl (trans)-octahydropyrrolo[3,4-c]pyrrole-2-carboxylate hemioxalate | 1818847-81-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: tert-butyl (trans)-octahydropyrrolo[3,4-c]pyrrole-2-carboxylate hemioxalate
• 英文别名: tert-butyl (3aS,6aS)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole-5-carboxylate;oxalic acid
• CAS: 1818847-81-2
• 化学式: C₂H₂O₄*2C₁₁H₂₀N₂O₂
• 分子量: 514.619
• InChiKey: OJCDSFQJZRKLGK-OZZZDHQUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.23
• 重原子数：
  21.0
• 可旋转键数：
  0.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  116.17
• 氢给体数：
  3.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  tert-butyl (trans)-octahydropyrrolo[3,4-c]pyrrole-2-carboxylate hemioxalate 在 ammonium hydroxide 、 二氧化碳 、 溶剂黄146 、 三乙胺 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 反应 2.67h， 生成
  参考文献：
  名称：

  [EN] SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES
  [FR] DÉRIVÉS DE PHÉNYL-1H-PYRROLO [2, 3-C] PYRIDINE SUBSTITUÉS

  摘要：

  The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN); and diabetes.

  公开号：

  WO2022253167A1

文献信息

• [EN] MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN<br/>[FR] MODULATEURS DE LA PROTÉINE PROTO-ONCOGÈNE DE LA FAMILLE MYC
  申请人：[en]NALO THERAPEUTICS

  公开号：WO2023163712A1

  公开（公告）日：2023-08-31

  Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disease where modulation of Myc family proteins is desired. Also disclosed herein are methods of using said compounds and compositions.
• [EN] EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA PROTÉINE DE LIAISON À L'EMOPAMIL (EBP) ET LEURS UTILISATIONS
  申请人：[en]BIOGEN MA INC.

  公开号：WO2024015503A1

  公开（公告）日：2024-01-18

  Provided are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.